By activating GLP-1 receptors, semaglutide helps: Stimulate insulin production when blood sugar is high Reduce glucagon secretion, which further lowers blood sugar Slow down digestion, promoting a feeling of fullness Decrease appetite by acting on brain centers controlling hunger The FDA has approved Ozempic for the treatment of type 2 diabetes, while Wegovy, a higher-dose formulation of semaglutide, is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
This can often be managedand the odor reducedby dividing the daily prescription into smaller, more frequent doses to improve absorption [2]
The FDA resolved the semaglutide and tirzepatide shortages in 2025, ending the broad shortage-based pathway that powered large-scale compounding, and in April 2026 proposed excluding these drugs from the 503B bulks list, with a comment period through June 29, 2026
Using an impure or improperly synthesized Tirzepatide could introduce unknown contaminants, leading to unpredictable and dangerous results
